TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03363581

Intervention type: BEHAVIORAL
Intervention: Food Preference
Description: Buffet meal to assess food preference

Intervention type: BEHAVIORAL
Intervention: Food Preference
Description: Buffet meal to assess food preference
Study: NCT05808556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sticker pads containing lavender and ylang ylang oil
Description: The sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days,

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
Study: NCT03800069

Intervention type: DEVICE
Intervention: Group K Diagnostic point of care device
Description: Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
Study: NCT02423343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study: NCT03114956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gauze
Description: Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
Study: NCT03114956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titanium brush
Description: Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air powder abrasion
Description: Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive
Description: A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
Study: NCT02423343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV
Study: NCT02142959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Lotion 0.5%
Description: Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Lotion 3%
Description: Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Study: NCT01498445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
Study: NCT03616834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib (eFT-508)
Description: Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
Study: NCT01936779

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement: fatty acid
Description: Consumption of n-3 fatty acids for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement: fatty acid
Description: Consumption of olive oil for 8 weeks.
Study: NCT02142959

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 3D conformal radiation therapy
Description: 45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
Study: NCT01063478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (in addition to standard radiation and chemotherapy)
Description: Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
Study: NCT04625920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SootheVR: AppliedVR, Los Angeles, California
Description: a head-mounted display

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SootheVR: AppliedVR, Los Angeles, California
Description: a head-mounted display
Study: NCT00149292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Study: NCT02142959

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal radiation therapy
Description: 45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal radiation therapy
Description: 45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
Study: NCT02049814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose
Description: Voglibose tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose tablets
Study: NCT00737906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical turbinate reduction procedure
Description: Surgical turbinate reduction using the COBLATION device
Study: NCT02027987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproate acid
Description: valproate acid is a common drug which is applied for epilepsy prevention and treatment.
Study: NCT02566382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopy arthrodesis of the shoulder
Description: The shoulder surgery will be realized under arthroscopy only
Study: NCT04731090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
Description: IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
Study: NCT00149292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04371614

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prime Time Sister Circle
Description: The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group.
Study: NCT01886274

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
Study: NCT06002295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Topical Cream
Description: After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylated Spirit
Description: After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day.
Study: NCT03853577

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TMS/EEG
Description: navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMS/EEG
Description: navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
Study: NCT05812105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Buddy Program
Description: The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
Study: NCT04731090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine culture, antibiotic prophylaxis and hydrophilic-coated ureteral access sheaths
Description: Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
Study: NCT00313885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT01503723

Intervention type: OTHER
Intervention: Determined by intended physician
Description: We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
Study: NCT02447536

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Denmark 1331 (Statens Serum Institute)
Description: See above

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Russia-I (Serum Institute of India)
Description: See above
Study: NCT03542136

Intervention type: DEVICE
Group type: OTHER
Intervention: VibrosSense Meter®
Description: A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
Study: NCT01498445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
Study: NCT00161434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: 1 gram daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo for 8 weeks
Study: NCT03994900

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling for HbNO assessment
Description: Blood sampling
Study: NCT02513810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom with 1 month DAPT
Description: The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioMatrix or Ultimaster with 6 to 12 months DAPT
Description: The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
Study: NCT02564913

Intervention type: OTHER
Intervention: clinical evaluation
Study: NCT02766803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin and micronized trans-resveratrol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin and micronized trans-resveratrol
Study: NCT02863484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery
Description: pealing of the outer layer of the cavernous sinus
Study: NCT01856530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Liquid metered-dose nasal spray, 24 IU, administered once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo nasal spray
Study: NCT03300947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 100 mcg/kg
Description: Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 300 mcg/kg
Description: Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 300 mcg/kg
Description: Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin 300 mcg/kg
Description: Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam 1 mg
Description: A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
Study: NCT02753595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Eribulin mesylate will be administered at 1.4 mg/m\^2 as IV infusion on Day 1 and 8 of 21-day cycle
Study: NCT02753595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)
Description: PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg as IV infusion on Day -1 and 7 of 21-day cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biologic: PEGylated recombinant human hyaluronidase
Description: PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
Study: NCT04037475

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: photodynamic therapy herpes labialis
Description: Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy herpes labialis
Description: Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.
Study: NCT04267289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: Automated, cognitive behavioral therapy delivered via a website. There are 8 sessions, each taking one to 1.5 hours to complete. Sessions are prerecorded and sequenced. Sessions are based on the principles of cognitive behavioral therapy and include techniques such as cognitive restructuring and behavioral activation. The entire program takes about 8 to 12 weeks to complete.
Study: NCT04560270

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples to determine ctDNA levels during chemotherapy
Study: NCT02171234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study: NCT01676935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: See arm description
Study: NCT03433469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO (orally)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT02985645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary sinus augmentation with CGF
Description: Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic implant valve approach - DIVA system
Description: The DIVA system will be used to apply the CGF to the maxillary sinus.